Testing a cholesterol drug to improve heart blood flow on scans
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies whether lowering LDL (“bad cholesterol”) with a PCSK-9 inhibitor (evolocumab) improves blood flow to the heart, measured by special PET scans. It’s for people over a certain age who have stable coronary artery disease and a higher risk of heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 50 years old (men) or 55 years old (women)
- Your LDL (bad cholesterol) is at least 70 mg/dL
- You have stable coronary artery disease with evidence of limited heart blood flow on prior testing (scan, angiogram/CT, or high coronary calcium score)
- If you take a statin, your dose has been the same for at least 3 months
- You have not had a heart attack or stroke
- You cannot currently use a PCSK-9 inhibitor (this drug) and must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
This trial tests whether a single injection of a PCSK9 inhibitor (a cholesterol-lowering medicine) can improve heart health after a stent procedure. It is for people who have a certain amount of fat buildup in their treated artery.
This trial tests whether a cholesterol-lowering medication called evolocumab (a PCSK9 inhibitor) can help people recover better after a specific type of stroke caused by clogged arteries. The study checks if lowering cholesterol further than usual statins do improves stroke outcomes and is safe.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
This trial tests a new medication (QLC7401) for people with high cholesterol that is not well controlled by their current treatment. It aims to see if the drug can help lower LDL-C (bad cholesterol) levels and reduce the risk of heart problems.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
Hear when a new Stable Coronary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.